AGN 195795
Alternative Names: AC 170472Latest Information Update: 18 May 2020
At a glance
- Originator ACADIA Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 12 Jul 2007 Discontinued - Phase-I/II for Glaucoma in USA (unspecified route)
- 17 May 2006 No development reported - Phase-I/II for Glaucoma in USA (unspecified route)